The drug resistance analysis of Group A beta-hemolytic streptococci and the detection of macrolide-resistant gene

Chinese Journal of Infection and Chemotherapy

Volumn 8, Issue 5, 2008, Pages 338-342

  Ma, Yao Ling ^a   Yang, Yong Hong ^a   Liang, Yun Mei ^a   Yu, Sang Jie ^a   Yuan, Lin ^a   Shen, Xu Zhuang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Macrolide; Phenotype; Streptococcus pyogenes

Indexed keywords

AZITHROMYCIN; BACTERIAL PROTEIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; JOSAMYCIN; MACROLIDE; OFLOXACIN; PENICILLIN G; PROTEIN ERMB; PROTEIN ERMTR; PROTEIN MEFA; RIBOSOME RNA; TETRACYCLINE; UNCLASSIFIED DRUG;

AGAR DILUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CHILD; CHINA; CHINESE; DRUG CHOICE; GENE AMPLIFICATION; GENE IDENTIFICATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PEDIATRIC HOSPITAL; PHENOTYPE; POLYMERASE CHAIN REACTION; PREVALENCE; RNA METHYLATION; STREPTOCOCCUS GROUP A; STREPTOCOCCUS PYOGENES;

EID: 53349128847     PISSN: 10097708     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Shibl A. Patterns of macrolide resistance determinants among S. pyogenes and S. pneumoniae in Saudi Arabia[J]. Int Med Res, 2005, 33(3):349-355.
2. Green M, Martin JM, Barbadora KA, et al. Reemergence of macrolide resistance in pharynegeal isolates of group A streptococci in southwestern Pennsylvania[J]. Antimicrob Agents Chmother, 2004, 48(2):473-476.
3. Erdem G, Ford J, Johnson D, et al. Erythromycin-resistance group A streptococci isolates collected between 2000 and 2005 in Oahu, Hawaii, and their emm types[J]. J Clin Microbiol, 2005, 43(5):2497-2499.
4. Szczypa K, Sadowy E, Izdebski R, et al. Group A Streptococci from invasive-disease episodes in Poland are remarkably divergent at the molecular level[J]. J Clin Microbiol, 2006, 40(11):3975-3979.
5. Robinson DA, Sutcliffe JA, Tewodros W, et al. Evolution and global dissemination of macrolide-resistant group A Streptococci[J]. Antimicrobial Agents Chemother, 2006, 50 (9):2903-2911.
6. Tewodros W, Kronvall G. M protein gene (emm type) analysis of group A beta-hemolytic Streptococci from ethiopia reveals unique patterns[J]. J Clin Microbiol, 2005, 43(9): 4369-4376.
7. Pérez-Trallero E, Montes M, Orden B, et al. Phenotypic and genotypic characterization of Streptococcus pyogenes isolates displaying the MLSB phenotype of macrolide resistance in spain, 1999 to 2005[J]. Antimicrobial Agents Chemother, 2007, 51(4):1228-1233.
8. Alos JI, Aracil B, Oteo J, et al. Significant increase in the prevalence of erythromycin-resistant, clindamycin-and miocamycin-susceptible (M phenotype) Streptococcus pyogenesin Spain[J]. J Antimicrob Chemother,2003, 51(2):333-337.
9. Katz KC, McGeer AJ, Duncan CL, et al. Emergence of macrolide resistance in throat culture isolates of group A streptococci in Ontario, Canada, in 2001 [J]. Antimicrob Agents Chemother, 2003, 47(7):2370-2372.
10. Martin JM, Green M, Barbadora KA, et al. Erythromycin-resistant group A streptococci in schoolchildren in Pittsburgh [J]. N Engl J Med, 2002,346 (16):1200-1206.
11. McGregor KF, Spratt BG. Identity and prevalence of multilocus sequence typing-defined clones of group A streptococci within a hospital setting[J]. J Clin Microbiol, 2005, 43(4): 1963-1967.
12. Capoor MR, Nair D, Deb M, et al. Resistance to erythromycin and rising penicillin MIC in Streptococcus pyogenes in India[J]. Jpn J Infect Dis, 2006, 59(5):334-336.
13. Chinese source.
14. Chinese source.
15. Chinese source.
16. Ho PL, Johnson DR, Yue AW, et al. Epidemiologic analysis of invasive and noninvasive group a Streptococcal isolates in Hong Kong [J]. J Clin Microbiol, 2003,43(3):937-942.
17. Ambile-Cuevas CF, Hermid-Esobedo C, Vivar R. Comparative in vitro activitiy of moxifloxacin by E-test against streptococcus pyogenes[J]. Clin Infect Dis,2001, 32(Suppl 1):S30-S32.
18. Chinese source.
19. Farrell DJ, Douthwaite S, Morrissey I, et al. Macrolide resistance by ribosomal mutation in clinical isolates of Streptococcus pneumoniae from the PROTEKT 1999-2000 study[J]. Antimicrob Agents Chemother, 2003, 47(6):1777-1783.
20. Lina G, Quaglia A, Reverdy ME, et al. Distribution of genes encoding resistance to macrolides, lincosamides, and streptogramins among staphylococci[J]. Antimicrob Agents Chemother, 1999,43 (5):1062-1066.
21. Pihlajamaki M, Kataja J, Seppala H, et al. Ribomal mutations in Streptococcus pneumoniae clinical isolates[J]. Antimicrob Agents Chemother, 2002, 46(3):654-658.
22. Canu A, Malbruny B, Coquemont M, et al. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae[J]. Antimicrob Agents Chemother, 2002, 46 (1):125-131.
23. Tait-Kamradt A, Davies T, Cronan M, et al. Mutations in 23SrRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage [J]. Antimicrob Agents Chemother, 2000, 44 (8): 2118-2125.
24. Syrogiannopoulos GA, Grivea IN, Ednie LM, et al. Antimicrobial susceptibility and macrolide resistance inducibility of St reptococcus pneumoniae carrying erm(A), erm(B), or mef (A)[J]. Antimicrob Agents Chemother, 2003, 47(8):2699-2702.
25. Silva-Costa C, Ramirez M, Melo-Cristino J, et al. Rapid Inversion of the prevalences of macrolide resistance phenotypes paralleled by a diversification of T and emm types among Streptococcus pyogenes in portugal[J]. Antimicrob Agents Chemother, 2005, 49(5):2109-2111.